Ingestion of vegetables rich in inorganic nitrate (NO3-) content has emerged as an effective method, via the formation of a nitrite (NO2-) intermediate, for acutely elevating vascular nitric oxide (NO) levels. As such a number of beneficial effects of NO3- ingestion have been demonstrated including the suggestion that platelet reactivity is reduced. I initially investigated whether inorganic NO3- supplementation might also reduce platelet reactivity in healthy volunteers and have determined the mechanisms involved in the effects seen. I conducted a randomised crossover study in 24 (12 of each sex) healthy subjects assessing the acute effects of potassium nitrate capsules (KNO3, 8 mmol) vs placebo (KCl) control capsule ingestion on platelet reactivity. Inorganic NO3- ingested via supplementation raised circulating NO3- and NO2- levels in both sexes and attenuated ex vivo platelet aggregation responses to adenosine diphosphate (ADP) and, albeit to a lesser extent, collagen but not epinephrine in male but not female volunteers. These inhibitory effects were associated with a reduced platelet P-selectin expression and elevated platelet cyclic guanosine monophosphate (cGMP) levels. In addition, I have shown that NO2- reduction to NO occurs at the level of the erythrocyte and not the platelet. These results demonstrate that inorganic NO3- ingestion, whether via the diet or through supplementation, results in a modest decrease in platelet reactivity in healthy males. I then sought to examine the effects of 6 weeks daily intake of NO3--rich beetroot juice versus a placebo NO3--deplete juice on endothelial and platelet function in a cohort of otherwise healthy non-diabetic untreated hypercholesterolaemics. In this randomised double blind placebo controlled parallel study 69 subjects were recruited. The primary end point was change in endothelial function determined using ultrasound flow-mediated dilatation (FMD). Secondary endpoints included change in pulse wave analysis (PWA), aortic pulse wave velocity (aPWV), platelet P-selectin and platelet monocyte aggregate (PMA) expression and plasma, urine and salivary NO3- and NO2- levels. Baseline characteristics, including lipid levels, were similar between the groups. Dietary NO3- caused an improvement in FMD of ~24% from 4.6%±2.2% to 5.7%±2.6% in the treatment group (p<0.001) not seen in the placebo group (4.5%±1.9% versus 4.3%±1.8% p=0.07). This improvement in FMD was also noted following acute administration of dietary NO3-. Small but significant improvements also occurred in aPWV and PWA augmentation index (p=0.04). The % of platelet monocyte aggregates was significantly reduced in the NO3- limb by 7.6% versus an increase of 10.1% in the placebo group (p=0.004). No adverse effects of dietary NO3- were detected. In this study population, chronic dietary NO3- ingestion improves endothelial function, vascular stiffness and platelet markers of atherogenesis in a cohort of hypercholesterolaemics who are otherwise at increased risk of cardiovascular disease (CVD). This thesis provides strong support for assessment of the potential of dietary NO3- as a primary prevention strategy to prevent atherothrombotic and atherogenic complications in larger cohorts.

Thesis (MNutrition (ITE))--Stellenbosch University, 2012. / ENGLISH ABSTRACT: Background Statins are drugs of known efficacy in the treatment of hypercholesterolaemia. However, statin-induced myopathy, an adverse effect of statins in up to 15% of its users, has warranted a reduction in the prescription dose or discontinuation of the drug. The exact mechanism of statin-induced myopathy is unknown, but the potential of Coenzyme Q10 (CoQ10) as treatment has been recognized due to decreased human plasma CoQ10 levels found after statin use and the concomitant role of CoQ10 in muscle function. Objectives This systematic review assessed the effect of CoQ10 supplementation on: the severity of statin-induced myopathic symptoms, levels of plasma creatine kinase, intramuscular and plasma CoQ10, as well as whether any adverse effects of CoQ10 supplementation such as abdominal pain, nausea and vomiting or headaches were experienced. Search methods Two searches for studies were conducted in The Cochrane Central Register of Controlled Trials (inception to March 2011 and inception to November 2011), MEDLINE (inception to March 2011 and inception to November 2011), Web of Science (inception to March 2011 and inception to November 2011), Science Direct (inception to March 2011 and inception to February 2012), Wiley Online Library (inception to March 2011 and inception to February 2012), Springerlink (inception to April 2011 and inception to February 2012), EBSCOhost [Academic Search Premier and CAB abstracts (inception to March 2011 and inception to February 2012), CINAHL (inception to March 2011 and inception to November 2011)], Scopus (inception to March 2011 and inception to November 2011) and Google Scholar (inception to March 2011 and inception to February 2012). Reference lists of articles were hand searched for relevant clinical trials. Only trials with a full text were included in the review. Selection criteria Randomised controlled trials (RCTs) were included with adult participants (mean of 18-64.99 years) of all race/ethnic groups and gender on statin therapy with reported myopathic symptoms from an unknown cause. The intervention was in the form of a pure oral supplement of CoQ10 irrespective of dose, duration and frequency, and the control in the form of a placebo, a similar antioxidant, or no intervention. Outcomes included the severity of myopathic symptoms, levels of plasma creatine kinase (U/L), intramuscular CoQ10 (μmol/kg) and plasma CoQ10 (μmol/L), as well as adverse effects of CoQ10. Data collection and analysis The principle investigator and one independent reviewer selected the studies, extracted data and assessed for risk of bias using the Cochrane Collaboration‘s tool for assessing risk of bias. Authors of relevant clinical trials were contacted for additional information. Results Two RCTs were included in the review, totaling 76 participants. A meta-analysis could not be performed, thus the review is narrative. There were an insufficient number of RCTs to confirm whether routine supplementation of CoQ10 improves statin-induced myopathic symptoms. Conclusions More and larger RCTs are required to determine the efficacy of CoQ10 supplementation in statin-induced myopathy. Consensus needs to be reached regarding the definition and measurement instrument/s of myopathy so that results of future studies can easily be compared and synthesized. / AFRIKAANSE OPSOMMING: Agtergrond Statiene is medikasie bekend vir die effektiewe behandeling van hipercholesterolemie. Statien-geïnduseerde miopatie is egter 'n newe-effek wat voorkom in tot 15% van gebruikers, wat 'n vermindering in die voorgeskrewe dosis of staking van die medikasie tot gevolg het. Die presiese meganisme van statien-geïnduseerde miopatie is onbekend, maar die potensiaal van Koënsiem Q10 (CoQ10) is geïdentifiseer as 'n moontlike behandeling aangesien menslike plasma CoQ10 vlakke verlaag na die gebruik van statiene en as gevolg van die rol van CoQ10 in spierfunksie. Doelwitte Hierdie sistematiese literatuuroorsig het die effek van CoQ10 supplementasie bepaal op: die graad van statien-geïnduseerde miopatiese simptome, plasma kreatien kinase vlakke, intra-muskulêre en plasma CoQ10 vlakke, asook die teenwoordigheid van enige newe-effekte van CoQ10 supplementasie soos abdominale pyn, naarheid en braking of hoofpyne. Soektogstrategie Twee soektogte vir studies is uitgevoer in The Cochrane Central Register of Controlled Trials (ontstaan tot Maart 2011 en ontstaan tot November 2011), MEDLINE (ontstaan tot Maart 2011 en ontstaan tot November 2011), Web of Science (ontstaan tot Maart 2011 en ontstaan tot November 2011), Science Direct (ontstaan tot Maart 2011 en ontstaan tot Februarie 2012), Wiley Online Library (ontstaan tot Maart 2011 en ontstaan tot Februarie 2012), Springerlink (ontstaan tot April 2011 en ontstaan tot Februarie 2012), EBSCOhost [Academic Search Premier en CAB abstracts (ontstaan tot Maart 2011 en ontstaan tot Februarie 2012), CINAHL (ontstaan tot Maart 2011 en ontstaan tot November 2011)], Scopus (ontstaan tot Maart 2011 en ontstaan tot November 2011) en Google Scholar (ontstaan tot Maart 2011 en ontstaan tot Februarie 2012). Verwysingslyste van artikels is ook met die hand nagegaan vir relevante kliniese proewe. Slegs kliniese proewe waarvan die volteks beskikbaar was, is ingesluit in die oorsig. Seleksiekriteria Ewekansige gekontroleerde proewe (EGP) is ingesluit met volwasse deelnemers (gemiddeld 18-64.99 jaar) van alle rasse/etniese groepe en geslag op statien-terapie met gerapporteerde miopatie simptome van onbekende oorsaak. Die intervensie was 'n suiwer orale supplement van CoQ10 ongeag die dosis, duurte en frekwensie, en die kontrole 'n plasebo, soortgelyke antioksidant, of geen intervensie. Uitkomste het ingesluit: die graad van miopatie simptome, vlakke van plasma kreatien kinase (U/L), intra-muskulêre CoQ10 (μmol/kg) en plasma CoQ10 (μmol/L), sowel as newe-effekte van CoQ10. Dataversameling en -analise Die hoof ondersoeker en een onafhanklike hersiener het die seleksie van studies en data-ekstraksie onderneem en die risiko vir sydigheid geassesseer deur gebruik te maak van die Cochrane Collaboration’s tool for assessing risk of bias. Outeurs van relevante kliniese proewe is geraadpleeg vir addisionele inligting Resultate Twee EGP is ingesluit in die oorsig met 'n totaal van 76 deelnemers. 'n Meta-analise kon nie uitgevoer word nie, dus is die oorsig beskrywend. Daar was te min EGP om te bewys dat roetine supplementasie van CoQ10 statien-geïnduseerde miopatiese simptome verbeter. Gevolgtrekkings Meer en groter EGP is nodig om die effektiwiteit van CoQ10 supplementasie in statien-geïnduseerde miopatie te bepaal. Konsensus moet bereik word ten opsigte van die definisie en metingsinstrument/e van miopatie sodat die resultate van toekomstige studies makliker vergelyk en verwerk kan word.

Cette thèse tente d’apporter, en la sociologisant, des éléments de réponse à une question émanant du monde médical : pourquoi des individus atteints d’hypercholestérolémie et donc surexposés à des risques cardio-vasculaires ne mettent-ils pas en application les conseils diététiques formulés par leur médecin ? Trois phases d’enquête ont été menées : 1) des entretiens d’experts, dans le but d’identifier les controverses qui ont transformé l’hypercholestérolémie en un problème de santé publique majeur ; 2) des entretiens individuels et collectifs auprès de « mangeurs à risques », afin de saisir les principaux freins au suivi des règles hygiéno-diététiques prescrites et les formes de régulation sociale de la pathologie ; et 3) une enquête quantitative, avec passation de questionnaires auprès de 800 individus, ayant pour but la description socio-démographique de la population d’étude et la validation des résultats qualitatifs. Si les rapports à l’alimentation et à la santé apparaissent comme étant en partie surdéterminés par des variables sociales et culturelles, les résultats invitent surtout à resituer les individus dans leurs contextes interactionnels et familiaux. Les décisions alimentaires et les manières de faire face à cette pathologie chronique ne sont pas construites dans une perspective individuelle. Au final, l’articulation entre la sociologie de l’alimentation et les champs de la santé, du risque, de la famille et du genre a permis de renouveler la problématique de l’observance et d’ouvrir un vaste territoire de recherches sur les effets du « manger ensemble » et du « vivre ensemble ». En cela, la thèse entend contribuer à une sociologie de la décision alimentaire. / This thesis attends answering a question originated from the medical world, by framing it through a sociological perspective: why do some hypercholesterolaemic individuals not comply with their doctor’s dietetic advice although being overexposed to cardiovascular risks? Three surveys were conducted: 1) some experts’ interviews, so as to identify the controversies that have led hypercholesterolaemia to be considered as a major public health problem; some in-depth interviews and a focus group with “at risk eaters”, in order to grasp the main obstacles to the dietary compliance and the forms of social regulation for the pathology; and 3) a quantitative survey, carried out by questionnaires among 800 people and developed with the aim of collecting sociodemographic data on the population, and validating the qualitative results. Notwithstanding that the relations with food and health are partly over-determined by social and cultural variables, results underlined the need to situate individuals in their interactional and family environment. Neither eating choices nor the ways to cope with this chronic pathology are constructed within an individual perspective. Connecting the sociology of food with other works from the health, risk, family and gender domains eventually enabled revitalizing the compliance issue and initiating a vast field of researches on the effects of “eating together” and “living together”. This thesis therefore intends contributing to a sociology of eating choices.

LDL-apheresis and haemorheopheresis are the most frequent methods of extracorporeal ellimination methods used for lowering the LDL cholesterol in patients with familial hypercholesterolaemia (FH). In case of failure of conservative therapy (represented by pharmacotherapy and/or dietary regime) these methods reprensent the effective and accessible solution for the clinical status characterized by high morbidity and mortality as well. The lipid components are the most frequent observed markers for the effeciveness of intervention. However, immunity with its effector molecules plays also essential role and there is suppose, that could also reflect the state and progress of atherosclerosis in FH patients. The aim of this thesis was to evaluate the levels of selected immunological markers (plasmatic glykoprotein α-2-macroglobulin, IL-10, soluble endoglin, soluble apoptotic factor sAPO-Fas and soluble form of adhesive P-selectin) and their changes after LDL-apheresis and haemorheopheresis employing enzyme immunoanalysis and immuno nephelometry. Totally, 12 patients were involved in this study, 3 were treated by haemorheopheresis, the rest 9 received LDL-apheresis. As a results, significant decreases in serum levels of α-2- macroglobulin, soluble endoglin and sAPO-1/Fas were recorded. Observed changes of...

A homeostase do colesterol é mediada por proteínas envolvidas na absorção (NPC1L1), regulação (SREBP1, SREBP2, SCAP), síntese (HMGCR) e remoção plasmática (LDLR). Os fármacos inibidores da síntese (vastatinas) e absorção (ezetimiba) do colesterol são potentes agentes hipocolesterolemiantes. Alterações em vários genes têm sido associadas a diferenças na resposta a diversos agentes terapêuticos. Com a finalidade de estudar os efeitos de hipolipemiantes e polimorfismos sobre a expressão dos genes HMGCR, LDLR, SREBF1a, SREBF2, SCAP e NPC1L1, foram selecionados 25 indivíduos com hipercolesterolemia familial (HF), 72 com hipercolesterolemia não familial (HNF) e 125 indivíduos normolipidêmicos e sem doença cardiovascular (NL). Os indivíduos HF foram tratados com sinvastatina (40 mg/dia/4 sem) combinada ou não com ezetimiba (10 mg/dia/4sem) e os HNF foram tratados com atorvastatina (10 mg/dia/4sem). Amostras de sangue foram obtidas antes e após o tratamento para a extração de DNA e RNA e analise do perfil lipídico sérico. A expressão de mRNA dos genes SREBF1a, SREBF2, SCAP, HMGCR, LDLR e NPC1L1 em células mononucleares do sangue periférico (CMSP) foi determinada por RT-PCR em tempo real empregando-se o gene da GAPD como controle endógeno. Os polimorfismos SREBF1a 36delG, SREBF2 G1784C e SCAP A2386G foram determinados por PCR-RFLP. Os indivíduos HF apresentaram maior expressão de mRNA dos genes NPC1L1, HMGCR e LDLR que os grupos HNF e NL (p<0,05). O efeito da atorvastatina sobre a expressão dos genes estudados parece depender da expressão basal nos indivíduos HNF. A variação da expressão após o tratamento com atorvastatina nos pacientes do grupo HNF esteve correlacionada nos genes: SREBF1a e SREBF2; SREBF1a e SCAP; SREBF1a e LDLR; SREBF2 e SCAP; SREBF2 e LDLR; HMGCR e LDLR. O tratamento com sinvastatina e ezetimiba não modificou o padrão de expressão dos genes estudados no grupo HF. Os polimorfismos SREBF2 G1784C e SCAP A2386G parecem estar relacionados com diminuição da expressão de mRNA após o tratamento com atorvastatina. Foi observado que os portadores do genótipo GG do polimorfismo SREBF2 G1784C apresentaram maiores concentrações séricas de colesterol total e LDL-C após o tratamento com atorvastatina. O polimorfismo SCAP A2386G parece estar associado com maiores concentrações de apoB em pacientes do grupo HNF antes do tratamento com atorvastatina. Os resultados são sugestivos que os genes HMGCR, LDLR e NPC1L1 são regulados diferentemente de acordo com o estado metabólico do indivíduo e a taxa de expressão de mRNA é influenciada pelos polimorfismos SREBF2 G1784C e SCAP A2386G após o tratamento com atorvastatina / The regulation of cholesterol is mediated by proteins involved in the absorption (NPC1L1), regulation (SREBP1, SREBP2, SCAP), synthesis (HMGCR) and removal of plasma cholesterol (LDLR). Potent hypocholesterolemic agents inhibit cholesterol synthesis (statins) and its absortion (ezetimibe). Changes in several genes have been associated to different responses to various therapeutic agents. In order to evaluate the association between genes involved in the metabolism of cholesterol and their response to lipid lowering drugs, patients with familial (FH, n = 25) and non familial hypercholesterolemia (NHF, n = 72) were selected. Additionally, 125 normolipidemic individuals and without cardiovascular disease were selected (NL). The HF group were treated with simvastatin (40 mg/day/4 weeks) combined or not with ezetimibe (10 mg/day/4weeks). The NHF group were treated with atorvastatin (10 mg/day/4weeks). Blood samples were obtained prior to and following treatment for extraction of DNA and RNA, and serum lipid profile analysis. The mRNA expression of SREBF1a, SREBF2, SCAP, HMGCR, LDLR, and NPC1L1 genes was determined by real time RT-PCR using the GAPD gene as endogenous control. The polymorphisms SREBF1a-36delG, SREBF2 G1784C, and SCAP A2386G were determined by PCR-RFLP. Individuals with HF showed higher expression of mRNA of genes NPC1L1, HMGCR and LDLR when compared with HNF and NL groups (p <0.05). The effect of atorvastatin on the gene expression seems to depend on the baseline expression in HNF subjects. The change of expression after treatment with atorvastatin in group HNF was correlated as followed: SREBF1a and SREBF2; SREBF1a and SCAP; SREBF1a and LDLR; SREBF2 and SCAP; SREBF2 and LDLR; HMGCR and LDLR. Treatment with simvastatin and ezetimibe did not change the gene-expression profile in HF group. The polymorphisms SREBF2 G1784C, and SCAP A2386G appear to be related to a decreased expression of mRNA after treatment with atorvastatin. HNF group Carriers of GG genotype of SREBF2 G1784C polymorphism had higher serum concentrations of total cholesterol and LDL-C after therapy. The SCAP A2386G polymorphism seems to be associated with higher concentrations of apoB in patients from HNF group prior to treatment with atorvastatin. The results suggest that the HMGCR, LDLR and NPC1L1 genes are regulated according to the metabolic status of the individual, and the expression rate of mRNA is influenced by SREBF2 G1784C and SCAP A2386G polymorphisms after atorvastatin therapy.

Submitted by admin tede (tede@pucgoias.edu.br) on 2016-10-07T13:20:43Z No. of bitstreams: 1 Sheila Adriana Pereira.pdf: 2003897 bytes, checksum: 206de26fdf0a454a14f8e59e44ef8daa (MD5) / Made available in DSpace on 2016-10-07T13:20:43Z (GMT). No. of bitstreams: 1 Sheila Adriana Pereira.pdf: 2003897 bytes, checksum: 206de26fdf0a454a14f8e59e44ef8daa (MD5) Previous issue date: 2016-06-28 / Obesity represents a global public health problem, being a disorder influenced by genetic and environmental factors. It is an important cause of morbidity and mortality worldwide and the disease characteristics, has been understood as a chronic disorder of inflammatory nature. Several studies of polymorphisms associated with the metabolic syndrome, has been performed in obese children and adolescents, demonstrating significant relationship with this pathology. The several inflammatory cytokines exert significant influence in the development and maintenance of obesity for her role in the regulation of energy homeostasis and metabolism. The aim of this study was to evaluate the association of the polymorphism of SNP 1082G / A in the interleukin-10 gene promoter with the Children and Youth obesity in 48 cases and 45 controls, associated with the lipid profile. In this study case-control was used to ARMS-PCR methodology for allelic determination. Of obese individuals, 27 (56%) had the genotype A / G, followed by 13 (27%) with genotype A / A and 8 (17%) with genotype G / G. Of the analyzed controls, 28 (62%) had Genotype A / G, followed by 9 (20%) with genotype A / A and 8 (18%) with genotype G / G. In the analysis it was found that the presence of the SNP-1082G / A polymorphism was similar in both groups, no representing risk factor to obesity. Also there was a significant difference in HDL cholesterol levels in both groups, linking obesity to low levels of HDL in adolescents and reforcing the relevance of this parameter. / A obesidade corresponde a um problema mundial de saúde pública, sendo uma desordem influenciada por fatores genéticos e ambientais. Consiste em uma importante causa de morbidade e mortalidade no mundo todo e, pelas características da doença, tem sido entendida como uma desordem crônica de natureza inflamatória. Diversos estudos de polimorfismos associados com a síndrome metabólica, tem sido realizados em crianças e adolescentes obesos, demonstrando significativa relação com essa doença. As diversas citocinas inflamatórias exercem influência significativa no desenvolvimento e na manutenção da obesidade por seu papel na regulação da homeostase energética e no metabolismo. O presente estudo teve como finalidade associar o polimorfismo da citocina anti-inflamatória IL-10 e a possível relação desta com a obesidade. Foi avaliado a associação do polimorfismo do SNP 1082G/A no promotor do gene da interleucina-10 com a obesidade infanto juvenil em 48 casos e 45 controles, associando com o perfil lipídico. Nesse estudo tipo caso-controle foi utilizada a metodologia de ARMS-PCR para a determinação alélica. Dos indivíduos com obesidade, 27 (56%) apresentaram o genótipo A/G, seguidos de 13 (27%) com o genótipo A/A e 8 (17%) com o genótipo G/G. Dos controles analisados, 28 (62%) apresentaram genótipo A/G, seguidos de 9 (20%) com genótipo A/A e 8 (18%) com o genótipo G/G. Nas análises foi verificado que a presença do polimorfismo SNP- 1082G/A foi semelhante nos dois grupos, apresentando maior prevalência de heterozigotos para o loco da IL-10. Conclui-se com o presente estudo que as frequências alélicas e genotípicas foram semelhantes nos dois grupos analisados não sendo possível sugerir tal alteração como fator de risco para obesidade. Foi evidenciada uma significativa diferença dos níveis séricos de colesterol HDL, reforçando-se a importância da avaliação desse parâmetro que se mostrou em níveis inferiores nos indivíduos obesos.

A homeostase do colesterol é mediada por proteínas envolvidas na absorção (NPC1L1), regulação (SREBP1, SREBP2, SCAP), síntese (HMGCR) e remoção plasmática (LDLR). Os fármacos inibidores da síntese (vastatinas) e absorção (ezetimiba) do colesterol são potentes agentes hipocolesterolemiantes. Alterações em vários genes têm sido associadas a diferenças na resposta a diversos agentes terapêuticos. Com a finalidade de estudar os efeitos de hipolipemiantes e polimorfismos sobre a expressão dos genes HMGCR, LDLR, SREBF1a, SREBF2, SCAP e NPC1L1, foram selecionados 25 indivíduos com hipercolesterolemia familial (HF), 72 com hipercolesterolemia não familial (HNF) e 125 indivíduos normolipidêmicos e sem doença cardiovascular (NL). Os indivíduos HF foram tratados com sinvastatina (40 mg/dia/4 sem) combinada ou não com ezetimiba (10 mg/dia/4sem) e os HNF foram tratados com atorvastatina (10 mg/dia/4sem). Amostras de sangue foram obtidas antes e após o tratamento para a extração de DNA e RNA e analise do perfil lipídico sérico. A expressão de mRNA dos genes SREBF1a, SREBF2, SCAP, HMGCR, LDLR e NPC1L1 em células mononucleares do sangue periférico (CMSP) foi determinada por RT-PCR em tempo real empregando-se o gene da GAPD como controle endógeno. Os polimorfismos SREBF1a 36delG, SREBF2 G1784C e SCAP A2386G foram determinados por PCR-RFLP. Os indivíduos HF apresentaram maior expressão de mRNA dos genes NPC1L1, HMGCR e LDLR que os grupos HNF e NL (p<0,05). O efeito da atorvastatina sobre a expressão dos genes estudados parece depender da expressão basal nos indivíduos HNF. A variação da expressão após o tratamento com atorvastatina nos pacientes do grupo HNF esteve correlacionada nos genes: SREBF1a e SREBF2; SREBF1a e SCAP; SREBF1a e LDLR; SREBF2 e SCAP; SREBF2 e LDLR; HMGCR e LDLR. O tratamento com sinvastatina e ezetimiba não modificou o padrão de expressão dos genes estudados no grupo HF. Os polimorfismos SREBF2 G1784C e SCAP A2386G parecem estar relacionados com diminuição da expressão de mRNA após o tratamento com atorvastatina. Foi observado que os portadores do genótipo GG do polimorfismo SREBF2 G1784C apresentaram maiores concentrações séricas de colesterol total e LDL-C após o tratamento com atorvastatina. O polimorfismo SCAP A2386G parece estar associado com maiores concentrações de apoB em pacientes do grupo HNF antes do tratamento com atorvastatina. Os resultados são sugestivos que os genes HMGCR, LDLR e NPC1L1 são regulados diferentemente de acordo com o estado metabólico do indivíduo e a taxa de expressão de mRNA é influenciada pelos polimorfismos SREBF2 G1784C e SCAP A2386G após o tratamento com atorvastatina / The regulation of cholesterol is mediated by proteins involved in the absorption (NPC1L1), regulation (SREBP1, SREBP2, SCAP), synthesis (HMGCR) and removal of plasma cholesterol (LDLR). Potent hypocholesterolemic agents inhibit cholesterol synthesis (statins) and its absortion (ezetimibe). Changes in several genes have been associated to different responses to various therapeutic agents. In order to evaluate the association between genes involved in the metabolism of cholesterol and their response to lipid lowering drugs, patients with familial (FH, n = 25) and non familial hypercholesterolemia (NHF, n = 72) were selected. Additionally, 125 normolipidemic individuals and without cardiovascular disease were selected (NL). The HF group were treated with simvastatin (40 mg/day/4 weeks) combined or not with ezetimibe (10 mg/day/4weeks). The NHF group were treated with atorvastatin (10 mg/day/4weeks). Blood samples were obtained prior to and following treatment for extraction of DNA and RNA, and serum lipid profile analysis. The mRNA expression of SREBF1a, SREBF2, SCAP, HMGCR, LDLR, and NPC1L1 genes was determined by real time RT-PCR using the GAPD gene as endogenous control. The polymorphisms SREBF1a-36delG, SREBF2 G1784C, and SCAP A2386G were determined by PCR-RFLP. Individuals with HF showed higher expression of mRNA of genes NPC1L1, HMGCR and LDLR when compared with HNF and NL groups (p <0.05). The effect of atorvastatin on the gene expression seems to depend on the baseline expression in HNF subjects. The change of expression after treatment with atorvastatin in group HNF was correlated as followed: SREBF1a and SREBF2; SREBF1a and SCAP; SREBF1a and LDLR; SREBF2 and SCAP; SREBF2 and LDLR; HMGCR and LDLR. Treatment with simvastatin and ezetimibe did not change the gene-expression profile in HF group. The polymorphisms SREBF2 G1784C, and SCAP A2386G appear to be related to a decreased expression of mRNA after treatment with atorvastatin. HNF group Carriers of GG genotype of SREBF2 G1784C polymorphism had higher serum concentrations of total cholesterol and LDL-C after therapy. The SCAP A2386G polymorphism seems to be associated with higher concentrations of apoB in patients from HNF group prior to treatment with atorvastatin. The results suggest that the HMGCR, LDLR and NPC1L1 genes are regulated according to the metabolic status of the individual, and the expression rate of mRNA is influenced by SREBF2 G1784C and SCAP A2386G polymorphisms after atorvastatin therapy.

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior / In mammals, the liver plays a central role in whole-body lipid metabolism. Unfortunately, dysregulation of these pathways has been implicated in hyperlipidemias. In recent years, a significant association between the trace element selenium and hypercholesterolaemia in human and animals has been reported. This study was designed to investigate a potential hypolipidaemic effect of diphenyl diselenide ((PhSe)2) in Triton WR-1339-induced hyperlipidaemia in mice. Triton was administered intraperitoneally (400 mg/kg) to overnight-fasted mice to develop acute hyperlipidaemia. (PhSe)2 was administered orally (10 mg/kg) 30 min before Triton. At 24 h after Triton injection, blood samples were collected to measure plasma lipid levels. The hepatic thiobarbituric acid reactive substances and ascorbic acid levels as well as catalase and glutathione peroxidase activity were recorded. (PhSe)2 administration significantly lowered total cholesterol, non-high- density lipoprotein-cholesterol and triglycerides,whilst it increased high-density lipoprotein-cholesterol levels in plasma of hyperlipidaemic mice. Neither oxidative stress nor the antioxidant effect of (PhSe)2 was observed in the mouse liver in this experimental protocol. These findings indicated that (PhSe)2 was able to lower plasma lipid concentrations. Further studies are needed to elucidate the exact mechanism by which (PhSe)2 exerted its hypolipidaemic effect in the management of hyperlipidaemia. / Nos mamíferos, o fígado desempenha um papel extremamente importante na manutenção da homeostase do metabolismo dos lipídios plasmáticos. Entretanto, problemas na regulação desses mecanismos têm sido implicados na ocorrência de dislipidemias (alterações na concentração adequada de lipídios no plasma). Nos últimos anos, tem sido evidenciada a existência de uma relação entre os níveis de selênio (Se) e o aumento nas concentrações plasmáticas de lipídios em humanos e animais. Dessa forma, o presente trabalho teve por objetivo investigar um possível efeito hipolipidêmico do (PhSe)2, um composto orgânico de Se, no modelo de hiperlipidemia aguda induzida por Triton WR-1339 em camundongos, bem como investigar se a hiperlipidemia aguda induzida pela administração intraperitonial (i.p.) de Triton WR-1339 altera parâmetros relacionados à ocorrência de dano oxidativo no tecido hepático de camundongos e determinar se o efeito antioxidante do (PhSe)2 está presente nesse processo. Para isso, o Triton WR-1339 foi injetado i.p. (400 mg/kg) em camundongos que estavam em jejum de 12 horas. O (PhSe)2 foi administrado oralmente (10 mg/kg) 30 minutos antes do Triton WR-1339. 24 horas após a injeção do Triton WR-1339, amostras de sangue foram coletadas para dosagem das concentrações de lipídios plasmáticos. Os níveis de espécies reativas ao ácido tiobarbitúrico (TBARS) e ácido ascórbico, bem como a atividade das enzimas catalase e glutationa peroxidase foram determinados no tecido hepático. A administração de (PhSe)2 foi capaz de prevenir o aumento nos níveis de colesterol total, colesterol não-HDL e triglicerídeos bem como aumentar os níveis de HDL-colesterol no plasma de camundongos hiperlipidêmicos. No protocolo experimental utilizado nesse estudo não foram observadas alterações nos parâmetros hepáticos de estresse oxidativo analisados. Conseqüentemente, o efeito antioxidante do (PhSe)2 não pode ser verificado. Os resultados obtidos nesse trabalho encorajam a realização de estudos posteriores no intuito de elucidar o exato mecanismo através do qual o (PhSe)2 exerce seu efeito hipolipidêmico.

La transplantation d’hépatocytes représente une alternative à la transplantation hépatique pour le traitement de certaines maladies métaboliques dont l’hypercholestérolémie familiale. Les cellules souches embryonnaires (ES) et les cellules souches pluripotentes induites (iPS) humaines représentent de nouvelles sources de cellules hépatiques. Nous avons mis au point une approche de différenciation des cellules souches humaines en cellules hépatiques et généré ainsi des cellules dérivées de cellules iPS de patients atteints d’hypercholestérolémie familiale. / Hepatocyte transplantation represents an alternative to liver for the treatment of metabolic diseases including familial hypercholesterolaemia. Embryonic stem cells (ES) and induced pluripotent stem cells (iPS) represent new sources of hepatic cells. We have developed an approach to differentiate human stem cells into hepatic cells and thus we have generated hepatic cells derived from iPS of familial hypercholesterolaemia patients.